The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14. It reported earnings in this window, a natural checkpoint for the thesis.
BellRing Brands, Inc.
BRBR · the NYSE · USD · Market cap $894M · 530 employees
BellRing Brands, Inc., together with its subsidiaries, provides various nutrition products in the United States.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 20:08 UTC · 15 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price10.56 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.70)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $10.84 to $18.07, base estimate $14.48 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.70, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
BellRing Brands, Inc. holds its Markup at $10.56. The statistical read favours the buyers, held for 65 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 65 days |
| Price at the screen | $10.56 |
| Valuation | 5.42 trailing · 5.82 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.51 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 115.23% | Below 33% | Interest-bearing debt is 115.2% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 29.48% | Below 49% | Money owed to the company is 29.5% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
BellRing Brands,'s business is in a permissible area, but its interest-bearing debt is about 115% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BRBR's ethical verdict changes
Today BRBR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 27% discount to our $14.48 fair value, 4.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 27.1% discount to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +37% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $14.48, with a range of $10.84 to $18.07, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsProtein Shakes Sell But Growth Stays Flat
Walk into any gym or supermarket aisle and the Premier Protein bottles stand out, yet the company behind them grows revenue at just 2 percent a year. At a forward multiple of 9 times earnings the valuation looks undemanding, and the ethical screen clears, but our opportunity rating stays at none because thin 7 percent margins and an unknown moat leave little room for durable outperformance.
Analysts still lean buy with a $13 median target, yet the modest growth and lack of visible competitive edge make this a pass for us. A defensive label does not automatically create value when sales barely move and the business offers no clear pricing power.
Low growth in packaged foods often signals a value trap rather than a bargain, especially when earnings can slip if input costs or shelf space shift. Analysis, not advice.
| Forward P/E | 5.8xpriced for continued growth |
| Trailing P/E | 5.4xvery cheap relative to earnings |
| EPS, trailing | 1.42 |
| EPS, forward | 1.32 |
| Revenue growth | +4.2%slow but positive growth |
| Profit margin | 7.3%thin but positive margins |
| FCF yield | 22.49% |
| Current ratio | 2.25comfortably covers its short-term bills |
| Beta | 0.51steadier than the market |
| Short interest, float | 0.13% |
| 52-week range | 7.33 - 35.67 |
| Market cap | $894M |
| Employees | 530 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBRBR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $14.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is It Worth Investing in BellRing Brands (BRBR) Based on Wall Street's Bullish Views? Zacks · 18 Sep 2026
- BellRing Brands (BRBR) Down 15% Since Last Earnings Report: Can It Rebound? Zacks · 3 Sep 2026
- BellRing Brands (BRBR) Q3 2026 Earnings Call Transcript Motley Fool · 11 Aug 2026
- Has BellRing Brands (BRBR) Fallen Far Enough To Look Undervalued? Simply Wall St. · 9 Aug 2026
- BellRing Brands (BRBR) Issues Flat Sales Guidance, Is The Stock Still 19% Undervalued? Simply Wall St. · 9 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.40 | -8.6% | · | $914 | -8.6% |
| 2 months | $15.01 | -42.7% | · | $573 | -42.7% |
| 3 months | $16.73 | -48.6% | · | $514 | -48.6% |
| 6 months | $32.67 | -73.7% | · | $263 | -73.7% |
| 1 year | $61.33 | -86.0% | · | $140 | -86.0% |
| 2 years | $57.35 | -85.0% | · | $150 | -85.0% |
| 3 years | $35.84 | -76.0% | · | $240 | -76.0% |
| 5 years | $28.38 | -69.7% | · | $303 | -69.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BRBR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.